Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
AC

NASDAQ · ACRV

Acrivon Therapeutics, Inc. Common Stock

Healthcare · Biotechnology

$1.74

Up+$0.07 (+4.19%)

Updated Nov 5, 2026, 3:42 AM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
47.65M
P/E ratio
-0.71
Dividend yield
0.00%
52-week range
$1.27 – $2.39
Volume
127.89K
Avg. volume
1.62M

Price performance · ACRV

ACRV price history

1M range · 0 trading sessions · Daily adjusted prices

ACRV does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ACRV news

The latest Smart Investors Daily articles mentioning ACRV.

Stock researchCompany · Overview

ACRV research

Overview

Company profile and research snapshot.

Company profile

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$21.83
Implied upside
—
Analysts
15
ACRV recent ratings
DateFirmRatingTarget
Jan 9, 2026Piper SandlerOverweight—
Nov 25, 2025HC Wainwright & Co.Buy—
Aug 14, 2025OppenheimerOutperform—
May 16, 2025Jones TradingHold—
May 15, 2025OppenheimerOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium

Timothy A. Yap, MBBS, Ph.D., FRCP, of The University of Texas MD Anderson Cancer Center to present results from the dose escalation phase of the ACR-2316 Phase 1/2 trial on November 20, 2026 Durable clinical activity, including confirmed complete and partial responses (RECIST 1.1) with ACR-2316 monotherapy in heavily pretreated, AP3-predicted tumor types, including endometrial and lung cancers Activity in K-Ras pathway mutated cancers and reported synthetic lethality for WEE1 inhibition in K-Ras

Yahoo · Oct 20, 2026

Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027

ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft models Prioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent activity and strong synergy with BCL-2 and menin inhibitors IND-enabling studies ongoing with IND submission on track for first half of 2027 WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical-stage biotechnol

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By